Chimeric nucleic acids encoding polypeptides comprising CD70...

Details Chimeric nucleic acids encoding polypeptides comprising CD70... Chimeric nucleic acids encoding polypeptides comprising CD70...

2011-03-15

2011-03-15

Gambel, Phillip (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S023500, C435S252300, C435S320100, C435S455000

Reexamination Certificate

active

07906638

ABSTRACT:
This invention relates to genes which encode accessory molecule ligands and their use for immunomodulation, vaccination and treatments of various human diseases, including malignancies and autoimmune diseases. This invention also describes the use of accessory molecule ligands which are made up of various domains and subdomain portions of molecules derived from the tumor necrosis factor family. The chimeric molecules of this invention contain unique properties which lead to the stabilization of their activities and thus greater usefulness in the treatment of diseases. Vectors for expressing genes which encode the accessory molecule ligands of this invention are also disclosed.

REFERENCES:
patent: 4990455 (1991-02-01), Yamagishi et al.
patent: 5422104 (1995-06-01), Fiers et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5486463 (1996-01-01), Lesslauer et al.
patent: 5519119 (1996-05-01), Yamada et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5565321 (1996-10-01), Spriggs et al.
patent: 5573924 (1996-11-01), Beckmann et al.
patent: 5606023 (1997-02-01), Chen et al.
patent: 5817516 (1998-10-01), Kehry et al.
patent: 5861310 (1999-01-01), Freeman et al.
patent: 6017527 (2000-01-01), Maraskovsky et al.
patent: 6106832 (2000-08-01), Spriggs et al.
patent: 7070771 (2006-07-01), Kipps et al.
patent: 7495090 (2009-02-01), Prussak et al.
patent: 7524944 (2009-04-01), Kipps et al.
patent: 7786282 (2010-08-01), Prussak et al.
patent: 2004/0209295 (2004-10-01), Schwabe et al.
patent: 0 317 641 (1989-05-01), None
patent: 0 585 943 (1993-03-01), None
patent: 0 675 200 (1995-10-01), None
patent: 1 016 721 (2000-07-01), None
patent: WO 91/02540 (1991-03-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 93/19777 (1993-10-01), None
patent: WO 93/24135 (1993-12-01), None
patent: WO 94/04570 (1994-03-01), None
patent: WO 94/04680 (1994-03-01), None
patent: WO 94/17196 (1994-08-01), None
patent: WO 95/14487 (1995-06-01), None
patent: WO 95/17202 (1995-06-01), None
patent: WO 95/18819 (1995-07-01), None
patent: WO 95/32627 (1995-12-01), None
patent: WO 96/03141 (1996-02-01), None
patent: WO 96/14876 (1996-05-01), None
patent: WO 96/18413 (1996-06-01), None
patent: WO 96/22370 (1996-07-01), None
patent: WO 98/21232 (1998-05-01), None
Addison, Christina L. et al., “Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model,”Proc. Natl. Acad. Sci. U.S.A., 92:8522-8526 (1995).
Alderson et al., “CD40 expression by human monocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40”,J. Exp. Med., 178: 669-674 (1993).
Ali, Munaf et al., “The use of DNA viruses as vectors for gene therapy”,Gene Therapy, 1:367-384 (1994).
Ali, Stuart Alvaro et al., “PCR-Ligation-PCR Mutagenesis: A Protocol for Creating Gene Fusions and Mutations”,BioTechniques, 18:746-750 (1995).
Armitage, Richard J. et al., “Molecular and biological characterization of a murine ligand for CD40”, Nature, 357:80-82 (1992).
Banchereau, Jacques et al., “Long-Term Human B Cell Lines Dependent on Interleukin-4 and Antibody to CD40,”Science, 251:70-72 (1991).
Berman, Joan W. et al., “Gene transfer in lymphoid cells: Expression of the Thy-1,2 antigen by Thy-1.1 BW5147 lymphoma cells transfected with unfractionated cellular DNA”,Proc. Natl. Acad. Sci. USA, 81:7176-7179 (1984).
Blieden, Timothy M. et al., “Class-I MHC Expression in the Mouse Lung Carcinoma, Line 1: A Model for Class-I Inducible Tumors”,Int. J. Cancer Supp., 6:82-89 (1991).
Boles, Eckhard et al., “A rapid and highly efficient method for PCR-based site-directed mutagenesis using only one new primer”,Curr. Genet., 28:197-198 (1995).
Boris-Lawrie, Kathleen A. et al., “Recent advances in retrovirus vector technology”,Current Opinion in Genetics and Development, 3:102-109 (1993).
Brody, Steven L. et al., “Adenovirus-mediated in Vivo Gene Transfer”,Ann. N. Y. Acad. Sci., 716:90-103 (1994).
Cadwell, R. Craig et al., “Randomization of Genes by PCR Mutagenesis”,PCR Methods and Applications, 2:28-33 (1992).
Cantwell, M.J. et al., “CD95 and FAS-ligand expression and apoptosis in rheumatoid arthritis”,Arthritis and Rheumatism, vol. 39, No. 9, Suppl., Sep. 1996, p. 287.
Cantwell, Mark et al., “Acquired CD40-ligand deficiency in chronic lymphocytic leukemia”,Nature Medicine, 3:984-989 (1997).
Cantwell, Mark J. et al., “Adenovirus Vector Infection of Chronic Lymphocytic Leukemia B Cells”,Blood, 88:4676-4683 (1996).
Carter, Barrie J., “Adeno-associated virus vectors”,Current Opinion in Biotechnology, 3:533-539 (1992).
Clark, Edward A. et al., “Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50”,Proc. Natl. Acad. Sci. U.S.A., 83:4494-4498 (1986).
Cooper, Mark J., “Noninfectious Gene Transfer and Expression Systems for Cancer Gene Therapy”,Seminars in Oncology, 23:172-187 (1996).
Cosman, David et al., “Cloning, sequence and expression of human interleukin-2 receptor”,Nature, 312:768-771 (1984).
Danko, Istvan et al., “Direct gene transfer into muscle”,Vaccine, 12:1499-1502 (1994).
Davis, Heather L. et al., “Direct Gene Transfer into Skeletal Muscle In Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression”,Human Gene Therapy, 4:151-159 (1993).
Deans, Robert J. et al., “Expression of an immunoglobulin heavy chain gene transfected into lymphocytes”,Proc. Natl. Acad. Sci. USA, 81:1292-1296 (1984).
DeMatteo, Ronald P. et al., “Gene Transfer to the Thymus”,Annals of Surgery, 222:229-242 (1995).
Dilloo, Dagmar et al., “CD40 Ligand Induces an Antileukemia Immune Response In Vivo”,Blood, 90:1927-1933 (1997).
Evan, Christopher et al., “Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-Arthritic Cytokine Gene to Human Joints with Rheumatoid Arthritis”,Human Gene Therapy, 7:1261-1280 (1996).
Fanslow, William C. et al., “Structural characteristics of CD40 ligand that determine biological function”,Seminars in Immunology, 6:267-278 (1994).
Felgner, Philip L. et al., “Improved Cationic Lipid Formulations for In Vivo Gene Therapy”,Ann. N. Y. Acad. Sci., 772:126-139 (1995).
Fisher, Lisa J. et al., “In vivo and ex vivo gene transfer to the brain”,Current Opinion in Neurobiology, 4:735-741 (1994).
Flotte, T. R. et al., “Adeno-associated virus vectors for gene therapy”,Gene Therapy, 2:357-362 (1995).
Furth, Priscilla A. et al., “Gene Transfer into Mammalian Cells by Jet Injection”,Hybridoma, 14:149-152 (1995).
Galle, Peter R. et al., “Involvement of the CD95 (APO-1/Fas) Receptor and Ligand in Liver Damage”,J. Exp. Med., 182:1223-1230 (1995).
Glorioso, J. C. et al., “Development and application of herpes simplex virus vectors for human gene therapy”,Annu. Rev. Microbiol., 49:675-710 (1995).
Goldspiel, Barry R. et al., “Human gene therapy”,Clinical Pharmacy, 12:488-505 (1993).
Graham, Frank L. et al., “Manipulation of Adenovirus Vectors”,Methods in Molecular Biology, 7(11):109-128 (1991).
Hengge, Ulrich R. et al., “Expression of Naked DNA in Human, Pig, and Mouse Skin”,Journal of Clinical Investigation, 97:2911-2916 (1996).
Henkel, Thomas et al., “Functional Analysis of Mutated cDNA Clones by Direct Use of PCR Products in in Vitro Transcription/Translation Reactions”,Analytical Biochemistry, 214:351-352 (1993).
Hollenbaugh, Diane et al., “The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity”,The EMBO Journal, 11:4313-4321 (1992).
Horton, Robert M., &

Affiliated with

Also associated with

Rating

Chimeric nucleic acids encoding polypeptides comprising CD70... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric nucleic acids encoding polypeptides comprising CD70..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric nucleic acids encoding polypeptides comprising CD70... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2692587